T1D Functional Cure being Tested in Humans: an Update from ViaCyte
December 3, 2020, CA
5:00 pm - 6:00 pm
JDRF is excited to share with you an update on using stem cell replacement therapy as a functional cure for T1D! ViaCyte, a JDRF-supported regenerative medicine company, has demonstrated that its stem cell-derived islet replacement cells, when effectively engrafted, are capable of producing insulin in T1D patients. We invite you to join Dr. Manasi Sinha Jaiman, VP of Clinical Development, and Mark Daniels, Director of Clinical Development, for an update on ViaCyte’s product candidates and the current progress in their human clinical trials. Advancing research in beta cell replacement is a core pillar of JDRF’s research strategy. We think you will find this fascinating and hope you will join us! A free event on Zoom. After RSVP'ing, please look for an email confirmation from the Northern CA Chapter of JDRF.
Dr. Manasi Sinha Jaiman, M.D., M.P.H
Vice President, Clinical Development
Dr. Jaiman has significant expertise in both drug and device development, especially for diabetes. Prior to ViaCyte, Dr. Jaiman was Senior Medical Director at Covance Clinical Development Services. She was also an attending physician at Harvard Medical School and Massachusetts General Hospital, where she was responsible for clinical care of type 1 and type 2 diabetes pediatric patients at Massachusetts General Hospital. Before joining Covance, she was involved in a variety of diabetes-related and obesity-related clinical research activities. In particular, she served as pediatric lead for three major clinical trials and co-investigator for 10 adult trials, evaluating improvements in glycemic control using a bihormonal, dual-chambered “bionic pancreas” programmed to deliver insulin and glucagon in response to real-time glucose sensor monitoring data. She was also a co-investigator in the development of a stable glucagon formulation using hyperinsulinemic-normoglycemic clamp techniques. Other research contributions included development of intradermal delivery of insulin and glucagon using a novel microneedle device, metabolic effects of gastric bypass surgery in young patients, and pharmacokinetic studies on multiple insulin types. Dr. Jaiman received her M.D. from Medical University of South Carolina and M.P.H. from Tulane University School of Public Health and Tropical Medicine. She completed her pediatric residency at Dartmouth-Hitchcock Medical Center and endocrinology fellowship at Massachusetts General Hospital, with a focus on type 1 diabetes research.
Director, Clinical Development
Mark Daniels is ViaCyte’s Director of Clinical Operations, has served in this position since June 2018, and has worked to oversee ViaCyte clinical trials since 2015. Prior to joining ViaCyte, Mr. Daniels spent 3 years as the Director of Clinical Operations at Dauntless Pharmaceutical where he was responsible for the clinical development of multiple therapeutic candidates in the Endocrine and Oncology indications. Prior to this his role at Dauntless, Mark spent 5 years as the Director of Clinical Operations at Cebix Incorporated where he was responsible for leading the C-peptide clinical development program from the first-in-human study to the completion of a large-scale, proof-of-efficacy Phase 2b international study, and also managed all phases of global clinical development studies at several pharmaceutical companies with a strong emphasis on neurology and oncology including Biogen Idec from 2007 to 2011, and Elan Pharmaceuticals from 2002 to 2007, and at Quintiles from 1997 to 2002.
Mr. Daniels received his Bachelor’s of Science degree in Psychobiology from the University of California, Los Angeles in 1997.
More from the Southern California Chapter